

## This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Transplantation</b>				
Graft-versus-host disease (GvHD)	Delta-like 1 (DLL1); DLL4	<p>Mouse studies suggest mAbs against DLL1 and DLL4 could be useful for preventing GvHD. In a mouse model for GvHD, transient treatment with mAbs against Dll1 and Dll4 decreased disease severity and increased survival compared with control mAbs. Next steps include characterizing the long-term effects of the anti-DLL1/DLL4 mAbs. The Genentech Inc. unit of Roche collaborated on the study but has not disclosed whether it has an anti-DLL1/DLL4 mAb in preclinical development. At least four companies have compounds targeting DLL4 in Phase I testing or earlier to treat various cancers.</p> <p><b>SciBX 6(12); doi:10.1038/scibx.2013.295</b>  <b>Published online March 28, 2013</b></p>	Patents filed by Genentech; licensing status undisclosed	<p>Tran, I.T. <i>et al. J. Clin. Invest.</i>; published online March 1, 2013; doi:10.1172/JCI65477</p> <p><b>Contact:</b> Ivan Maillard, University of Michigan, Ann Arbor, Mich.  e-mail: <a href="mailto:imaillar@umich.edu">imaillar@umich.edu</a></p>